Memorial Sloan Kettering Westchester
West Harrison, NY
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Classifications
Explore trials based on treatment classification/type.
Targets
Explore trials based on treatment targets.
MSK Service
Filter trials based on MSK Service
Accepting patients
Stopping Maintenance Therapy
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
Learn more- Maintenance
- Myeloma Service
- 19-422
Accepting patients
NUTRIVENTION-4
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 2
- Myeloma Service
- 20-198
Accepting patients
Melphalan With or Without Siltuximab
Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
Learn more- Monoclonal Antibody
- Interleukin 6 (IL-6)
- Post-Autologous Stem Cell Transplant
- Pre-Autologous Stem Cell Transplant
- Phase 2
- Myeloma Service
Accepting patients
Talquetamab Consolidation After BCMA CAR-T
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- GPRC5D
- Post-CAR T
- Phase 2
- Myeloma Service
- 23-072
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- CD3
- Phase 1
- Myeloma Service
Accepting patients
Isatuximab After Allogeneic Stem Cell Transplant
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Learn more- Monoclonal Antibody
- CD38
- Phase 2
- Transplant Service
- 23-119
Accepting patients
CyBorD Plus Daratumumab
A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)
Learn more- Monoclonal Antibody
- CD38
- Quadruplet Therapy
- Phase 2
- Myeloma Service
- 22-424
Accepting patients
Identifying Barriers to Cellular Therapy
Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD
Learn more- Observational Trial
- Transplant Service
- 23-166
Accepting patients
Genetic Studies
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Learn more- Myeloma Service